Vendor Intelligence Report: Paramount Peptides

Published 12 Jun 2026. 26-page investigative report on who is behind Paramount Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 65 Finnrick lab tests, Paramount Peptides records 45 pass / 20 fail for a 69% overall pass rate. The signal is uneven: Semaglutide and Retatrutide are the comparatively stronger reads, while CJC-1295 and BPC-157 sit at the weak end. The full report shows how product ratings move under stricter grading and why the vendor average is less useful than the molecule-by-molecule view.

The marketing story is cleaner than the records. Domain history, California filings, and the first usable archive place the current operation in a much newer window than the advertised 12-year, in-house manufacturer narrative. The listed Irvine presence resolves to a virtual-office setting, and the report traces the branded lab-building imagery without turning the photo issue into a substitute for testing data.

The regulatory signal comes through the operator network, not a direct state-board action against Paramount. The report ties Paramount's personnel trail to Alpha BioMed, then places that link beside Ohio Board of Pharmacy records describing Alpha BioMed products as unlicensed-source, misbranded dangerous drugs in clinic inventory. That distinction matters, but it still weighs on compliance confidence.

Paramount also markets like a retail peptide brand: affiliate links, coupon pages, X promoters, an expo trail, and a vendor-dedicated Reddit guide carrying a referral code. Its COA lookup helps with lot visibility but does not resolve Finnrick's weak-product failures, including captured mass-content reporting and blank lab-field issues.

Inside the full report:

  • Appendix A with full per-product pass/fail rates, methodology-divergence charts, and spark-grid trajectories
  • California filing, domain, Wayback, and trademark timeline behind the age claim
  • Address, virtual-office, lab-imagery, and Dr. Victor Prisk criticism exhibits
  • Ohio Board of Pharmacy extracts for Ageless Medica and Cryo Ohio naming Alpha BioMed products
  • Affiliate scan across X, coupon sites, and Reddit referral-code content
  • COA lookup captures, including Janoshik Wolverine Blend and BPC-157 result limitations

Risk assessment

  • Product-specific quality risk: CJC-1295, Survodutide, BPC-157 — high: Finnrick ratings are 29.44% for CJC-1295, 46.31% for Survodutide, and 51.2% for BPC-157; these products should not inherit Paramount's stronger Semaglutide and Retatrutide record.
  • Misleading corporate-history and manufacturing claims — high: The 12-year, in-house, Southern California lab presentation conflicts with an October 2023 domain, November 2023 LLC, Regus address, and digitally branded lab-building imagery.
  • Regulatory exposure through Alpha BioMed network — high: Ohio Board of Pharmacy clinic actions identified Alpha BioMed products as misbranded and Alpha BioMed as unlicensed and not FDA-registered; records tie Alpha BioMed and Paramount to the same operator network.
  • Affiliate-promotion and consumer-use marketing risk — high: The scan found 17 promoters, 14 with referral code or link, and only 3 clear disclosures, alongside consumer-facing posts, subreddit guides, and body-composition claims.
  • COA transparency risk — medium: Captured Janoshik and COA-lookup examples emphasize mass content, contain blank lab fields, and do not provide the purity evidence needed to resolve Finnrick's product-specific failures.